Gland Pharma Limited has received shareholder approval to reappoint Mr. Udo Johannes Vetter and appoint Mr. William Robert Keller as Independent Directors following a remote e-voting process. The voting, which concluded on July 18, 2026, sanctioned commissions on profits as remuneration for these directors and approved a revision of remuneration for existing Independent Director Mr. Essaji Goolam Vahanvati. These appointments strengthen the company's board governance structure for the next five years.

The postal ballot was conducted pursuant to Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. D Soumya, Associate Partner at RVR & Associates, Company Secretaries, served as the Scrutinizer for the process. The remote e-voting period commenced on June 19, 2026, and members holding shares as on June 12, 2026, were eligible to participate.

Director Tenures and Profiles

Mr. Udo Johannes Vetter has been reappointed for a second term of five consecutive years, effective from July 21, 2026, to July 20, 2031. He holds a degree in Clinical Pharmacy from the University of Washington and has extensive experience, including roles at Schering-Plough Corp. and as Managing Director of Vetter Inject GmbH & Co. KG. He currently serves as Chairman of the ITM Group, Germany.

Mr. William Robert Keller has been appointed as an Independent Director for a period of five consecutive years with effect from June 15, 2026, to June 14, 2031. Aged 78, Mr. Keller brings over 40 years of experience in the pharmaceutical and biotechnology sectors, having held management positions at Roche in South America and Asia. He currently serves as an Independent Director of Wuxi Biologics and Hua Medicine.

Voting Results Summary

All five resolutions presented to the shareholders were passed with the requisite majority. The total number of votes cast across the resolutions was 14,87,41,512. The table below details the voting outcomes for each resolution.

Key Voting Breakdown

The resolution to reappoint Mr. Udo Johannes Vetter saw 86.90% of votes in favour, with Public Institutions casting 19,48,082 votes against the proposal. Conversely, the special resolution to appoint Mr. William Robert Keller received 99.11% approval, with Public Institutions recording 13,22,387 votes against it.

For the ordinary resolutions regarding remuneration, shareholder support was higher. The proposal to consider commission on profits for Mr. Vetter received 99.18% approval, while the similar resolution for Mr. Keller was passed with 99.12% votes in favour. The revision of commission for Mr. Essaji Goolam Vahanvati was approved by 99.18% of the votes polled. The Promoter and Promoter Group voted 100% in favour of all resolutions. The results were declared on July 20, 2026.

Gland Pharma witnessed a notable block trade on the National Stock Exchange (NSE), with approximately 1,00,468 shares changing hands in a single transaction. The trade was executed at a price of ₹2489.60 per share, aggregating to a total deal value of ₹25.01 crores.

Block Trade Details

The following table summarises the key parameters of the block trade recorded on the NSE:

Block trades of this scale are typically executed by institutional investors or large market participants and are carried out outside the regular order book to minimise market impact. The transaction in Gland Pharma reflects considerable institutional interest in the stock at the prevailing price level.